Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Tretinoin Capsules, 10 mg, the generic version of Vesanoid Capsules, 10 mg, of Hoffmann La Roche, Inc. (which is no longer being marketed in the United States).
According to IMS Health sales data for the 12 month period ending October 2016, the Vesanoid Capsules, 10 mg market (includes brand and all available therapeutic equivalents) achieved annual sales of approximately $22.0 million*.
Glenmark’s current portfolio consists of 112 products authorized for distribution in the U.S. marketplace and 63 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
All brand names and trademarks are the property of their respective owners.
Shares of Glenmark Pharmaceuticals Ltd. was last trading in BSE at Rs.889.95 as compared to the previous close of Rs. 889.1. The total number of shares traded during the day was 51005 in over 1480 trades.
The stock hit an intraday high of Rs. 905.8 and intraday low of 883.5. The net turnover during the day was Rs. 45554949.
*IMS Health National Sales Perspectives: Retail & Non-Retail, October 2016